Clinical Trial Update: Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating nivolumab in combination with 177Lu-DOTA0-Tyr3-Octreotate for extensive-stage small cell lung cancer has completed with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer
• Small Cell Lung Cancer Extensive Stage

Drugs mentioned

• 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTA0-Tyr3-Octreotate)
• nivolumab (nivolumab)

Snippet

Sponsor: Georgetown University | Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-16